PF-06821497 + Docetaxel + Enzalutamide
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Trial Timeline
Oct 21, 2024 → Oct 29, 2028
NCT ID
NCT06551324About PF-06821497 + Docetaxel + Enzalutamide
PF-06821497 + Docetaxel + Enzalutamide is a phase 3 stage product being developed by Pfizer for Metastatic Castrate Resistant Prostate Cancer (mCRPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06551324. Target conditions include Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate Resistant Prostate Cancer (mCRPC) were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06551324 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Castrate Resistant Prostate Cancer (mCRPC)